EVLO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 22:55):

Stats
Dzisiejszy wolumen	22 122.00
Średni wolumen	33 335.00
Kapitalizacja rynkowa	825 752
EPS	$0 ( 2024-03-21 )
Następna data zysków	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-07	Bodmer Mark	Buy	6 625	Common Stock
2023-11-08	Bodmer Mark	Sell	3 163	Common Stock
2023-11-07	Bodmer Mark	Sell	6 625	Restricted Stock Units
2023-11-07	Mchale Duncan	Buy	6 500	Common Stock
2023-11-08	Mchale Duncan	Sell	3 103	Common Stock

INSIDER POWER
86.63
Last 96 transactions
Buy: 11 679 076 \| Sell: 749 652

Evelo Biosciences Inc Korelacja

10 Najbardziej pozytywne korelacje
YJ	0.981
RPTX	0.978
CLFD	0.977
LGMK	0.977
CREG	0.972
JAGX	0.971
CFRX	0.965
HOL	0.963
MMAT	0.963
SLNG	0.963

10 Najbardziej negatywne korelacje
BRIV	-0.986
ENTF	-0.986
ORIA	-0.984
PRLH	-0.984
PPYA	-0.984
IVCP	-0.983
HCNE	-0.983
PWUP	-0.983
BIOS	-0.983
CBRG	-0.983

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Evelo Biosciences Inc Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-26.28

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-26.28

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-3.09

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.37

Financial Reports:

No articles found.

Evelo Biosciences Inc

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Aktualne aktualizacje dla Evelo Biosciences Inc [EVLO]

Upcoming Earnings Alert